文献速递临床试验与 GCP真实世界研究与卫生经济

OPTION-DM:糖尿病周围神经痛最佳治疗路径的多中心双盲交叉试验方案

Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial.
PubMed 文献 · Trials · 2018-10-22

主要结局为各路径最后随访周7天平均24小时疼痛评分(11点NRS)的差异,旨在确定最具临床获益、成本效果和耐受性的治疗路径。

要点

  • 三种路径:阿米替林加普瑞巴林、普瑞巴林加阿米替林、度洛西汀加普瑞巴林。
  • 主要结局为路径最后随访周7天平均24小时疼痛评分(11点NRS)。
  • 所有受试者接受全部三种路径,随机决定顺序。

核心结论

  • 该试验旨在填补NICE推荐缺乏稳健证据的缺陷,确定糖尿病周围神经痛最临床获益、成本效果和耐受的治疗路径。

研究设计与样本

  • 多中心、双盲、中心分层、多周期交叉随机对照试验,等比例分配至六种治疗顺序(1:1:1:1:1:1)。

主要发现

  • 原文未报告结果,仅报告研究设计。

关键数值与推荐

  • 主要结局为各路径最后随访周7天平均24小时疼痛评分(11点NRS)的差异。
  • 次要结局包括疗效、成本效果、安全性、患者感知耐受性和亚组分析,在各路径第6周和第16周测量。

临床怎么用

  • 研究结果将针对当前临床实践中的治疗路径,具有外推性。
  • 将提供健康经济学结局及患者表型是否预测治疗反应的信息。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The number of people with diabetes is growing rapidly. Diabetes can cause nerve damage leading to severe pain in the feet, legs and hands, which is known as diabetic peripheral neuropathic pain (DPNP). In the UK, the National Institute for Health and Care Excellence (NICE) recommends amitriptyline, duloxetine, pregabalin or gabapentin as initial treatment for DPNP. If this is not effective, adding one of the other drugs in combination with the first is recommended. NICE points out that these recommendations are not based on robust evidence. The OPTION-DM randomised controlled trial has been designed to address this evidence deficit, with the aims of determining the most clinically beneficial, cost-effective and tolerated treatment pathway for patients with DPNP. METHODS/DESIGN: A multicentre, double-blind, centre-stratified, multi-period crossover study with equal allocation to sequences (1:1:1:1:1:1) of treatment pathways. Three hundred and ninety-two participants will be recruited from secondary care DPNP centres in the UK. There are three treatment pathways: amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline and duloxetine supplemented with pregabalin. All participants will receive all three pathways and randomisation will determine the order in which they are received. The primary outcome is the difference between 7-day average 24-h pain scores on an 11-point NRS scale measured during the final follow-up week of the treatment pathway. Secondary outcomes for efficacy, cost-effectiveness, safety, patient-perceived tolerability and subgroup analysis will be measured at week 6 and week 16 of each pathway. DISCUSSION: The study includes direct comparisons of the mainstay treatment for DPNP. This novel study is designed to examine treatment pathways and capture clinically relevant outcomes which will make the results generalisable to current clinical practice. The study will also provide information on health economic outcomes and will include a subgroup study to provide information on whether patient phenotypes predict response to treatment. TRIAL REGISTRATION: ISRCTN17545443 . Registered on 12 September 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Selvarajah D, Petrie J, White D, et al. Multicentre, double-blind, crossover trial to identify the Optimal Pathway for TreatIng neurOpathic paiN in Diabetes Mellitus (OPTION-DM): study protocol for a randomised controlled trial. Trials. 2018. PMID: 30348206. doi:10.1186/s13063-018-2959-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。